SRZNSurrozen, Inc./DE
0.2×
Less likely than average to be bought by an AI rollup
Top 83% of the Russell 3000. How it works
Clinical-stage biotech developing antibody-based Wnt pathway therapeutics for ophthalmic diseases like macular edema.
Deal filings
| Filed | Form | Acquirer | Price | Premium |
|---|---|---|---|---|
| Jul 15, 2021 | DEFM14A | — | $10.00 | 0% |
Key numbers
- Revenue
- —
- Operating margin
- —
- EBITDA
- —
- Net debt / EBITDA
- —
Financials
No XBRL financials yet.